QuickView: Resminostat refocused cancer strategy
4SC has fresh funds and a renewed clinical strategy for its lead epigenetic anti-cancer agent resminostat. A €29m (gross) capital increase in July provides the funds to commence a potentially pivotal Phase II trial in Europe with resminostat in CTCL in Q216. Data are expected in H218, with potential EU filing/approval possible in H219. Meanwhile, clinical data in 2016 from two Phase II studies being conducted by Japanese partner Yakult, in liver and lung cancer, offer the prospect of stimulating fresh partnership and/or financing discussions. Our fair value was recently upgraded to €141m from €115m.4SC is a biotechnology company that researches and develops drugs primarily for the treatment of cancer diseases. The Company has special expertise and clinical products in the field of epigenetics. 4SC's compounds aim to enable new therapeutic methods that offer improved efficacy and tolerability compared to the treatments available to date, both as monotherapy and in combination with other drugs. This approach is intended to enhance treatment benefits for affected patients, coupled with improvements to their life expectancy and quality of life. Adjusted for 1- for -5 stock split, April 2015Adjusted for 1- for -5 stock split, April 2015
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.